SeLux Diagnostics is a technology company.
SeLux Diagnostics has raised $105.0M across 3 funding rounds.
SeLux Diagnostics has raised $105.0M in total across 3 funding rounds.
SeLux Diagnostics has raised $105.0M in total across 3 funding rounds.
SeLux Diagnostics's investors include Vasudev Bailey, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Endeavor Venture Funds, Fusion Fund, Shubhra Jain.
SeLux Diagnostics (SeLux) is a Boston‑area diagnostics company building a rapid phenotypic antimicrobial susceptibility testing (AST) platform to deliver precise antibiotic susceptibility results in hours rather than days, targeting faster, personalized treatment for bacterial infections and to combat antimicrobial resistance (AMR).[2][4]
High‑Level Overview
SeLux’s mission is to enable precision diagnostics for infectious diseases by closing the gap between infectious disease (ID) identification and susceptibility testing so clinicians can make faster, personalized antibiotic decisions.[3][4]
Their investment/product philosophy centers on rapid, phenotypic AST using a proprietary Next Generation Phenotyping (NGP) System that emphasizes speed, comprehensive panels, and updatable breakpoints to improve antibiotic stewardship and clinical outcomes.[4][3]
Key sectors: clinical diagnostics, microbiology, infectious disease, and laboratory automation—particularly rapid AST for bloodstream infections and other serious bacterial infections.[2][4]
Impact on the startup/clinical ecosystem: SeLux’s NGP approach aims to shorten lab turnaround times (results in ~5.5 hours from isolates), reduce inappropriate antibiotic use, and set a new standard for phenotypic AST that could reshape hospital lab workflows and antimicrobial stewardship programs.[4][2]
Origin Story
SeLux was founded in 2014 and is headquartered in the Boston/Charlestown, Massachusetts area.[1][5]
The company was formed by an interdisciplinary team combining microbiology, biochemistry, engineering, software, and algorithm design with clinical experts in microbiology, infectious disease, and machine learning to tackle the rising global threat of AMR.[3]
The idea arose from the pressing need for rapid phenotypic AST that preserves accuracy while delivering actionable results within a single clinical shift; early product development emphasized a 384‑well panel design and an integrated NGP System (inoculator, separator, analyzer) to overcome prior “panel real estate” limits and deliver precise MICs and broad dilution series.[4][2]
Early traction and pivotal moments include multiple FDA 510(k) clearances for components of their system (e.g., Separator and panel clearances) and successive funding rounds supporting commercialization and R&D expansion.[5][2]
Core Differentiators
Role in the Broader Tech & Healthcare Landscape
SeLux rides two converging trends: the urgent global push to address AMR and the clinical‑laboratory demand for faster, actionable diagnostics that support precision medicine and antibiotic stewardship.[3][4]
Timing matters because rising AMR, evolving regulatory breakpoints, and hospital pressure to shorten length of stay and reduce inappropriate antibiotic use create strong demand for rapid, accurate AST platforms.[3][4]
Market forces in their favor include payer and hospital incentives to reduce costly bloodstream infection complications, enhanced focus on stewardship programs, and technological readiness for integrated lab automation.[4][5]
SeLux’s success could influence the broader ecosystem by accelerating adoption of rapid phenotypic AST, prompting competitors and regulators to prioritize updatable breakpoint workflows, and driving changes in lab procurement toward single‑platform systems that combine speed, breadth, and regulatory agility.[4][5]
Quick Take & Future Outlook
Near term, expect SeLux to continue commercial roll‑out of its NGP System, expand antibiotic menus (e.g., gram‑negative panels), pursue additional regulatory clearances, and scale manufacturing and sales into hospital microbiology labs.[5][4]
Key trends shaping their journey: ongoing AMR pressure, adoption of rapid diagnostics in clinical pathways, reimbursement and hospital economic evaluations of rapid AST, and the ability to maintain regulatory compliance as breakpoints evolve.[3][4]
Risks and considerations include competition from other rapid AST and molecular platforms, the need for hospital lab validation and workflow changes, and the capital intensity of scaling diagnostic manufacturing and service support.[5][4]
If SeLux delivers on rapid, accurate, and updatable phenotypic AST at scale, it could meaningfully speed targeted therapy, strengthen stewardship programs, and become a reference platform in acute care microbiology—fulfilling its stated mission to preserve antibiotic utility and improve patient outcomes.[3][4]
SeLux Diagnostics has raised $105.0M across 3 funding rounds. Most recently, it raised $48.0M Series D in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $48.0M Series D | Vasudev Bailey, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Polaris Partners, RA Capital, Section 32, Anne Wojcicki | |
| Feb 1, 2022 | $50.0M Series C | Vasudev Bailey, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Polaris Partners, RA Capital, Section 32, Anne Wojcicki | |
| Nov 1, 2018 | $7.0M Series B | Endeavor Venture Funds, Fusion Fund, Shubhra Jain |